With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
ABT trades against a final fair-value range of $87.24-$127.26, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
A macroeconomic shock would compress ABT's normalized 17% operating margins. Given the rigid 67% dividend payout ratioPayout ratioDividends per share divided by EPS. Measures how much of earnings the company distributes versus retains for reinvestment., resultant FCFFree cash flowOperating cash flow minus capital expenditures. The cash a business generates after maintaining and growing its asset base — the closest accounting proxy for owner-economics. drops would severely restrict capital flexibility for M&A and R&D, forcing increased balance sheet leverageLeverageThe proportion of debt in the company's capital structure. Commonly measured as Debt/EBITDA, Debt/Equity, or Net Debt/EBITDA..
Next-gen competitive continuous glucose monitors or GLP-1 drug advancements severely erode FreeStyle Libre adoption, cratering high-margin medical device growth.
Persistent input cost inflation and generic competition fundamentally impair the pediatric and adult nutrition segments' operating leverage.
Sustained FCF deterioration due to aggressive pricing pressure forces a dividend cut, shattering the mature dividend payer archetype premium.
| Line item | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
|---|---|---|---|---|---|---|
| Revenue | $43.08B | $43.65B+1.3% | $40.11B-8.1% | $41.95B+4.6% | $44.33B+5.7% | +0.7% |
| Gross profit | $24.54B | $24.51B | $22.13B | $23.24B | $25.01B | +0.5% |
| Operating income | $8.43B | $8.36B | $6.48B | $6.83B | $8.05B | -1.1% |
| Net income | $7.07B | $6.93B-2.0% | $5.72B-17.5% | $13.40B+134.3% | $6.52B-51.3% | -2.0% |
| EPS (diluted) | — | $3.91 | $3.26 | $7.64 | $3.72 | -1.2% |
| EBITDA | $12.28B | $12.13B | $10.54B | $10.79B | $12.08B | -0.4% |
| R&D | $2.74B | $2.89B | $2.74B | $2.84B | $2.94B | +1.8% |
| SG&A | $11.32B | $11.25B | $10.95B | $11.70B | $12.33B | +2.2% |
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Deterioration versus the report thesis |
| Piotroski F-score remaining below 3 for three consecutive quarters. | Monitor | Deterioration versus the report thesis |
| Dividend payout ratio structurally exceeding 85% of free cash flow. | Monitor | Deterioration versus the report thesis |
